Your browser doesn't support javascript.
loading
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Döhner, Hartmut; Weber, Daniela; Krzykalla, Julia; Fiedler, Walter; Kühn, Michael W M; Schroeder, Thomas; Mayer, Karin; Lübbert, Michael; Wattad, Mohammed; Götze, Katharina; Fransecky, Lars; Koller, Elisabeth; Wulf, Gerald; Schleicher, Jan; Ringhoffer, Mark; Greil, Richard; Hertenstein, Bernd; Krauter, Jürgen; Martens, Uwe M; Nachbaur, David; Samra, Maisun Abu; Machherndl-Spandl, Sigrid; Basara, Nadezda; Leis, Claudia; Schrade, Anika; Kapp-Schwoerer, Silke; Cocciardi, Sibylle; Bullinger, Lars; Thol, Felicitas; Heuser, Michael; Paschka, Peter; Gaidzik, Verena I; Saadati, Maral; Benner, Axel; Schlenk, Richard F; Döhner, Konstanze; Ganser, Arnold.
Afiliación
  • Döhner H; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany. Electronic address: hartmut.doehner@uniklinik-ulm.de.
  • Weber D; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Krzykalla J; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
  • Fiedler W; Hubertus Wald University Cancer Center, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
  • Kühn MWM; Department of Hematology, Medical Oncology & Pneumology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Schroeder T; Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
  • Mayer K; Department of Hematology, Oncology, University Hospital Bonn, Bonn, Germany.
  • Lübbert M; Department of Medicine I, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Wattad M; Klinik für Hämatologie, Internistische Onkologie & Stammzelltransplantation, Evang. Krankenhaus Essen-Werden, Essen-Werden, Germany; Klinikum Hochsauerland, Meschede, Germany.
  • Götze K; Department of Medicine III, Hematology and Medical Oncology, Technical University of Munich, Munich, Germany.
  • Fransecky L; Department of Internal Medicine II, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany.
  • Koller E; Department of Internal Medicine III, Hanusch Krankenhaus Wien, Wien, Austria.
  • Wulf G; Department of Hematology and Medical Oncology, University Medicine Göttingen, Göttingen, Germany.
  • Schleicher J; Klinik für Hämatologie, Onkologie, Stammzelltransplantation und Palliativmedizin, Klinikum Stuttgart, Stuttgart, Germany.
  • Ringhoffer M; Department of Internal Medicine III, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.
  • Greil R; 3rd Medical Department Paracelsus Medical University Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute Center for Clinical Trials and Immunology Trials, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria.
  • Hertenstein B; Department of Hematology and Oncology, Klinikum Bremen-Mitte, Bremen, Germany.
  • Krauter J; Medizinische Klinik III, Städtisches Klinikum Braunschweig, Braunschweig, Germany.
  • Martens UM; Klinik für Innere Medizin III, SLK-Kliniken Heilbronn, Heilbronn, Germany.
  • Nachbaur D; Universitätsklinik für Innere Medizin V, Medizinische Universität Innsbruck, Innsbruck, Austria.
  • Samra MA; Medizinische Klinik IV, Universitätsklinikum Gießen, Gießen, Germany.
  • Machherndl-Spandl S; Department of Hematology and Oncology, Ordensklinikum Elisabethinen Linz, Linz, Austria.
  • Basara N; Medizinische Klinik I, Malteser Krankenhaus St Franziskus-Hospital Flensburg, Flensburg, Germany.
  • Leis C; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Schrade A; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Kapp-Schwoerer S; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Cocciardi S; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Bullinger L; Department of Hematology, Oncology and Cancer Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin, Germany.
  • Thol F; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
  • Heuser M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
  • Paschka P; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Gaidzik VI; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Saadati M; Freelance Statistician, Saadati Solutions, Ladenburg, Germany.
  • Benner A; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
  • Schlenk RF; National Center of Tumor Diseases, German Cancer Research Center, Heidelberg, Germany; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Döhner K; Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Ganser A; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Lancet Haematol ; 10(7): e495-e509, 2023 Jul.
Article en En | MEDLINE | ID: mdl-37187198
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline Idioma: En Revista: Lancet Haematol Año: 2023 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline Idioma: En Revista: Lancet Haematol Año: 2023 Tipo del documento: Article